Phenylalanine
CAS 63-91-2
Phenylalanine (CAS 63-91-2) is a Phase 3 pharmaceutical compound with 7 bioactivity targets and 7 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29934.654838709677 nM | 31 | - |
| - | IC50 | 50265.51166666667 nM | 14 | - |
| - | MIC | 8765.384615384615 nM | 13 | - |
| - | Potency | 15543.800000000001 nM | 9 | - |
| - | Ki | 18985.746666666666 nM | 2 | - |
| Large neutral amino acids transporter small subunit 1 Transporter |
IC50 | 4.16 | - | Homo sapiens |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 Ion channel |
Ki | 6.01 | - | Mus musculus |
| L-type amino acid transporter 1 Transporter |
Ki | 4.26 | - | Rattus norvegicus |
| Intestinal alkaline phosphatase Enzyme |
IC50 | 4.1 | - | Bos taurus |
| Probable G-protein coupled receptor 139 GPCR |
IC50 | 4.51 | - | Homo sapiens |
| Intestinal-type alkaline phosphatase Enzyme |
IC50 | 4 | - | Homo sapiens |
| E3 ubiquitin-protein ligase XIAP Unclassified |
IC50 | 4.1 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Foetal growth restriction | 15 | 65.578 | 10070531 |
| Compartment syndrome | 10 | 49.88 | 10010121 |
| Device related sepsis | 10 | 46.946 | 10069802 |
| Vasoplegia syndrome | 9 | 46.876 | 10067080 |
| Infantile apnoea | 8 | 44.765 | 10077321 |
| Selective eating disorder | 8 | 40.104 | 10078069 |
| Coma scale abnormal | 9 | 38.934 | 10069709 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| GPR139 GPR139 |
Agonist | 3.490000009536743 pEC50 | 24826842 |
| GPR139 GPR139 |
Agonist | 3.059999942779541 pKi | 26349500 |
| GPR139 GPR139 |
Agonist | 4.510000228881836 pIC50 | 26349500 |
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Phenylalanine | 8156 | SU | MTHSPL |
| PHENYLALANINE | 8156 | SU | MTHSPL |
| phenylalanine | 8156 | SU | MTHSPL |
| phenylalanine | 8156 | IN | RXNORM |
| L-phenylalanine | 8156 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Phenylalanine used for in pharmaceutical contexts?
Phenylalanine (CAS 63-91-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Phenylalanine?
Phenylalanine has 7 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Compartment syndrome, Device related sepsis, Vasoplegia syndrome, Infantile apnoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Phenylalanine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Phenylalanine with EU status "permitted".
What clinical phase is Phenylalanine in?
Phenylalanine is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Phenylalanine?
Phenylalanine has 12 bioactivity rows in this page query. Rendered target entries include Large neutral amino acids transporter small subunit 1, Voltage-dependent calcium channel subunit alpha-2/delta-1, L-type amino acid transporter 1, Intestinal alkaline phosphatase, Probable G-protein coupled receptor 139.